Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy

Lung CancerPleural Diseases

Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%)

J Clin Med

Djordjevic F, Ljujic K, Stanic N, Nikolic N, Markovic I, Spasic J

doi: 10.3390/jcm14176200

Lung Cancer

Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial

Lancet Respir Med

Shi Y, Wu L, Ji Y, Chen G, Li B, Bi M, Yang R, Miao L, Zhang G, Gao H, Sun L, Zhang M, Cang S, Sun M, Yao W, Pan Z, Cui J, Xiao Y, Wang Q, NCT04143607 Study Group

doi: 10.1016/S2213-2600(25)00121-3

Lung Cancer

Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial

Clin Lung Cancer

Yang JC, Chen YM, Batra U, Do KH, Sitthideatphaiboon P, Danchaivijitr P, Lee KY, Chindaprasirt J, Yang CT, Chang GC, Charoentum C, Ungtrakul T, Moran JIH, Hartmaier R, Igwegbe I, Gont A, Haskins M, Xu W, Riess JW

doi: 10.1016/j.cllc.2025.10.018

COMMENTED

COPD

Efficacy and safety of ensifentrine in treatment of COPD: a systematic review and meta-analysis of clinical trials

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Ther Adv Respir Dis

Hammadeh BM, Younis OM, Alsufi MI, Idrees M, Hussein AM, Aldalati AY, Qtaishat FA, Qatawneh B, Bugazia A, Hamed RA

doi: 10.1177/17534666251347775

Lung Cancer

A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer

Sci Rep

Sa-Nguansai S, Rattanasiri S, Pornsuriyasak P, Numthavaj P, McKay GJ, Attia J, Thakkinstian A

doi: 10.1038/s41598-025-05823-2

RECOMMENDED

Lung Cancer

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Wang Y, Zhang L, Zhan J, Wen L, Zhao X, Sun H, Chen X, Zhang Y, Chen G, Zhao Y, Huang Y, Fang W, Zhang L, Sun D, Yang Y

doi: 10.1016/j.lungcan.2026.108914

RECOMMENDED

Pulmonary Hypertension

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Am J Respir Crit Care Med

Montani D, McLaughlin VV, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Escribano Subias P, Feldman J, Meyer GM, Olsson KM, Coulet F, Manimaran S, Zhao Y, Lau A, de Oliveira Pena J, Badesch DB, Humbert M

doi: 10.1164/rccm.202409-1698OC

Further Publications

Patient Factors and Clinical Efficacy of Early Identification and Treatment of COPD and Asthma

Am J Respir Crit Care Med

Tardif A, Whitmore GA, Vandemheen KL, Bergeron C, Boulet LP, Côté A, McIvor RA, Penz E, Field SK, Lemière C, Mayers I, Bhutani M, Azher T, Lougheed MD, Gupta S, Ezer N, Licskai CJ, Hernandez P, Ainslie M, Alvarez GG, Mulpuru S, Aaron SD

doi: 10.1164/rccm.202505-1260OC

RECOMMENDED

Interstitial Lung DiseasePulmonary Hypertension

Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Dagher C, Akiki M, Swanson K, Carollo B, Fiscus G, Farber HW, Parikh R

doi: 10.3390/jcm14155177

Related content

Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%)

Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial

Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial

Efficacy and safety of ensifentrine in treatment of COPD: a systematic review and meta-analysis of clinical trials

A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)

Patient Factors and Clinical Efficacy of Early Identification and Treatment of COPD and Asthma

Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights